TG Therapeutics Inc (TGTX)vsVertex Pharmaceuticals Inc (VRTX)
TGTX
TG Therapeutics Inc
$31.82
+5.29%
HEALTHCARE · Cap: $4.83B
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 1847% more annual revenue ($12.00B vs $616.29M). TGTX leads profitability with a 72.6% profit margin vs 32.9%. TGTX appears more attractively valued with a PEG of 1.61. VRTX earns a higher WallStSmart Score of 66/100 (B-).
TGTX
Buy63
out of 100
Grade: C+
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-53.0%
Fair Value
$18.84
Current Price
$31.82
$12.98 premium
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 103 in profit
Keeps 73 of every $100 in revenue as profit
Revenue surging 78.0% year-over-year
Strong operational efficiency at 26.2%
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Earnings declined 6.1%
Distress zone — elevated risk
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : TGTX
The strongest argument for TGTX centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 72.6% and operating margin at 26.2%. Revenue growth of 78.0% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : TGTX
The primary concerns for TGTX are PEG Ratio, EPS Growth, Altman Z-Score.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
TGTX profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.
TGTX carries more volatility with a beta of 1.86 — expect wider price swings.
TGTX is growing revenue faster at 78.0% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 63/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
TG Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?